We are proud to share a recently published feature in The Mycophile Quarterly (the newsletter of the North American Mycological Association) by Avery Stempel.

The article, titled "Psilocybin-Containing Mushrooms as an End-of-Life Transition Tool," examines the mounting research, clinical perspectives, and personal stories surrounding the use of psilocybin for existential dread and end-of-life distress.

The piece features valuable insights from leaders across the field, including clinical health psychologist Dr. Linda Carlson on her research with the Canadian Cancer Society, integrative palliative care physician Dr. Sunil Aggarwal, and advocates Julie Netherland and Corinne Carey.

In the article, TheraPsil’s Director of Communications, John Gilchrist, sat down with Avery to discuss practitioner training, the current regulatory landscape in Canada, and the major hurdles terminally ill patients face when seeking legal access.

"Patients in palliative care do not experience suffering on a research timeline."

The feature also highlights the story of Pete Pearson—a terminally ill Canadian who was granted Medical Assistance in Dying (MAiD) but repeatedly denied legal access to psilocybin therapy—underscoring why TheraPsil continues to advocate for legal, compassionate access pathways outside of clinical trials.